Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
argenx SE (ARGX.BR)
Breda, NL
argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, with its subcutaneous ENHANZE formulation also undergoing preclinical assessment. Beyond its lead product, argenx SE maintains an active pipeline of immunology-focused programs. This includes cusatuzumab, targeted at hematological cancers and high-risk myelodysplastic syndromes (MDS); ARGX-119, an antibody designed to inhibit muscle-specific tyrosine kinase; ARGX-117, slated for severe autoimmune disorders; ARGX-118, aimed at mitigating airway inflammation; and ARGX-120, another candidate for the treatment of autoimmune diseases. The firm also engages in collaborations for additional investigational products, such as ARGX-115 for cancer therapy, ARGX-112 which targets the interleukin-22 receptor, and ARGX-114, an antibody engineered to block the MET receptor. argenx SE has forged strategic alliances with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S. It also holds numerous collaboration and licensing agreements with partners including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., the University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. Established in 2008, argenx SE is headquartered in Breda, the Netherlands.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.01% | +0.75% | +2.38% | -0.68% | -10.26% | -2.59% | +40.00% | +88.60% | +234.39% | +6,051.54% | +8,737.97% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 10 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+92.2% ★ Q4'25: +254.1% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+59.4% ★ Q4'25: +603.4% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+13.4% ★ Q4'25: +15.9% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+23.4% ★ Q4'25: +27.4% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+34.0% ★ Q4'25: +89.7% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+1.3% ★ Q4'25: +12.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.08× ★ Q4'25: 0.03× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 28 Rev. Ana. 11 EPS Ana. |
Dec 2027 30 Rev. Ana. 13 EPS Ana. |
Dec 2028 14 Rev. Ana. 9 EPS Ana. |
Dec 2029 15 Rev. Ana. 11 EPS Ana. |
Dec 2030 21 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.57M
est: 5.86M (-22.1%)
|
7.49M
est: 10.33M (-27.4%)
|
15.47M
est: 17.87M (-13.4%)
|
43.69M
est: 49.04M (-10.9%)
|
24.57M
est: 50.94M (-51.8%)
|
78.46M
est: 93.10M (-15.7%)
|
50.58M
est: 72.22M (-30.0%)
|
528.27M
est: 511.37M (+3.3%)
|
410.75M
est: 445.91M (-7.9%)
|
1.23B
est: 1.22B (+0.4%)
|
2.25B
est: 2.15B (+4.7%)
|
4.32B
est: 4.21B (+2.7%)
|
5.96B
5.65B – 6.20B
+41.6% YoY
|
7.29B
6.65B – 9.20B
+22.3% YoY
|
8.60B
7.98B – 9.99B
+17.9% YoY
|
9.78B
9.09B – 11.37B
+13.8% YoY
|
11.05B
10.26B – 12.84B
+12.9% YoY
|
| EBITDA |
-12.38M
est: -3.46M (-257.3%)
|
-16.53M
est: -23.43M (+29.5%)
|
-22.17M
est: -30.57M (+27.5%)
|
-32.44M
est: -55.10M (+41.1%)
|
-93.06M
est: -29.24M (-218.3%)
|
-173.36M
est: -136.95M (-26.6%)
|
-601.03M
est: -190.05M (-216.3%)
|
-392.78M
est: -270.17M (-45.4%)
|
-622.78M
est: -642.07M (+3.0%)
|
-192.29M
est: -1.34B (+85.6%)
|
-16.32M
est: -3.90B (+99.6%)
|
1.01B
est: -1.41B (+171.6%)
|
-2.00B
-2.08B – -1.89B
-41.6% YoY
|
-2.44B
-3.08B – -2.23B
-22.3% YoY
|
-2.88B
-3.35B – -2.67B
-17.9% YoY
|
-3.28B
-3.81B – -3.04B
-13.8% YoY
|
-3.70B
-4.30B – -3.44B
-12.9% YoY
|
| EBIT |
-12.54M
est: -3.59M (-249.7%)
|
-16.74M
est: -25.81M (+35.1%)
|
-22.52M
est: -32.18M (+30.0%)
|
-32.97M
est: -56.19M (+41.3%)
|
-93.63M
est: -21.22M (-341.1%)
|
-175.78M
est: -227.13M (+22.6%)
|
-604.95M
est: -250.05M (-141.9%)
|
-398.65M
est: -355.48M (-12.1%)
|
-727.12M
est: -844.79M (+13.9%)
|
-303.59M
est: -1.76B (+82.8%)
|
-17.84M
est: -5.13B (+99.7%)
|
1.01B
est: -1.49B (+167.5%)
|
-2.12B
-2.20B – -2.01B
-41.6% YoY
|
-2.59B
-3.27B – -2.36B
-22.3% YoY
|
-3.05B
-3.55B – -2.84B
-17.9% YoY
|
-3.48B
-4.04B – -3.23B
-13.8% YoY
|
-3.93B
-4.56B – -3.65B
-12.9% YoY
|
| Net Income |
-12.54M
est: -55.55M (+77.4%)
|
-16.74M
est: -24.78M (+32.5%)
|
-22.48M
est: -31.57M (+28.8%)
|
-33.68M
est: -56.08M (+39.9%)
|
-76.23M
est: -25.99M (-193.4%)
|
-181.21M
est: -184.93M (+2.0%)
|
-608.46M
est: -228.22M (-166.6%)
|
-408.27M
est: -324.44M (-25.8%)
|
-709.59M
est: -771.04M (+8.0%)
|
-295.05M
est: -1.61B (+81.6%)
|
833.04M
est: -4.68B (+117.8%)
|
1.34B
est: 1.17B (+15.3%)
|
1.77B
1.57B – 2.08B
+52.1% YoY
|
2.41B
1.94B – 3.46B
+36.2% YoY
|
3.03B
2.75B – 3.67B
+25.4% YoY
|
3.52B
3.20B – 4.27B
+16.3% YoY
|
3.94B
3.57B – 4.77B
+11.8% YoY
|
| SGA |
4.21M
est: 8.16M (-48.4%)
|
5.38M
est: 8.36M (-35.6%)
|
7.37M
est: 10.16M (-27.4%)
|
14.93M
est: 18.40M (-18.8%)
|
27.47M
est: 11.52M (+138.4%)
|
72.15M
est: 76.23M (-5.4%)
|
170.55M
est: 100.48M (+69.7%)
|
305.52M
est: 128.55M (+137.7%)
|
469.92M
est: 305.50M (+53.8%)
|
709.54M
est: 636.78M (+11.4%)
|
1.05B
est: 1.85B (-43.2%)
|
1.42B
est: 2.61B (-45.4%)
|
3.69B
3.50B – 3.84B
+41.6% YoY
|
4.52B
4.12B – 5.70B
+22.3% YoY
|
5.33B
4.95B – 6.19B
+17.9% YoY
|
6.06B
5.63B – 7.05B
+13.8% YoY
|
6.85B
6.36B – 7.96B
+12.9% YoY
|
| EPS |
-0.80
est: -0.85 (+6.1%)
|
-1.06
est: -0.98 (-7.7%)
|
-1.19
est: -0.87 (-37.0%)
|
-1.37
est: -1.08 (-26.9%)
|
-2.12
est: -1.70 (-24.9%)
|
-4.69
est: -3.11 (-50.7%)
|
-13.40
est: -12.68 (-5.6%)
|
-7.74
est: -7.86 (+1.6%)
|
-13.05
est: -14.93 (+12.6%)
|
-5.16
est: -4.73 (-9.2%)
|
13.92
est: 1.68 (+726.4%)
|
21.94
est: 17.66 (+24.3%)
|
26.85
23.79 – 31.43
+52.1% YoY
|
36.56
29.31 – 52.40
+36.2% YoY
|
45.86
41.62 – 55.55
+25.4% YoY
|
53.35
48.42 – 64.62
+16.3% YoY
|
59.62
54.11 – 72.22
+11.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-15 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Karen Massey | Chief Operating Officer | 2M | female |
| Timothy Van Hauwermeiren EMBA | Co-Founder, Chief Executive Officer & Executive Director | 1M | male |
| Karl Gubitz | Chief Financial Officer | 848.8K | male |
| Beth DelGiacco | Vice President and Global Head of Corporate Communications & Investor Relations | — | female |
| Filip Borgions | Chief Technology Innovation Officer | — | male |
| Hans de Haard Ir | Co-Founder & Member of Board Advisors | — | — |
| Arjen Lemmen | Vice President of Corporate Development & Strategy | — | male |
| Achim Plueckebaum | Global Head of Digital Technologies | — | male |
| Luc Truyen | Chief Medical Officer | — | male |
| Malini Moorthy | General Counsel & Corporate Secretary | — | female |
| Marc Schorpion | Global Head of Human Resources | — | male |
| Peter Ulrichts | Chief Scientific Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARGX.BR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
